Compare APYX & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APYX | EMBC |
|---|---|---|
| Founded | 1982 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.4M | 207.1M |
| IPO Year | 1995 | 2021 |
| Metric | APYX | EMBC |
|---|---|---|
| Price | $4.12 | $3.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $6.50 | ★ $18.50 |
| AVG Volume (30 Days) | 101.7K | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 6.88% |
| EPS Growth | 19.40 | ★ 20.90 |
| EPS | N/A | ★ 0.67 |
| Revenue | N/A | N/A |
| Revenue This Year | $11.93 | $1.17 |
| Revenue Next Year | $11.01 | N/A |
| P/E Ratio | ★ N/A | $5.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.59 | $2.77 |
| 52 Week High | $5.08 | $15.55 |
| Indicator | APYX | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 48.77 |
| Support Level | $3.85 | $3.03 |
| Resistance Level | $4.29 | $3.48 |
| Average True Range (ATR) | 0.27 | 0.14 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 26.74 | 66.27 |
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.